Stimdia Medical

Executive Summary

Stimdia Medical is a private medical device company developing implantable neurostimulation systems for severe respiratory disorders caused by diaphragm dysfunction or paralysis. Founded in 2015 and headquartered in Minneapolis, the company's technology directly stimulates the phrenic nerve to restore natural breathing, offering a potential alternative to mechanical ventilation for patients with conditions such as spinal cord injury, neuromuscular disease, or phrenic nerve damage. By targeting the underlying neural pathway, Stimdia aims to improve patient outcomes, reduce dependence on ventilators, and lower healthcare costs associated with long-term respiratory support.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial results40% success
• Q4 2026FDA Investigational Device Exemption (IDE) approval50% success
• Q1 2027Series B or significant grant funding announcement30% success